Shares of Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company gained 3-7 percent in the opening trade on Friday on the back of USFDA approval for Xelpros which is used to treat open-angle Glaucoma or Ocular Hypertension.
The company announced USFDA (US Food and Drug Administration) approval for the new drug application (NDA) of Xelprostm (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
This approval is from Sun Pharma’s Halol (Gujarat, India) facility.
At 09:18 hrs Sun Pharmaceutical Industries was quoting at Rs 664.10, up 2.19 percent and Sun Pharma Advanced Research Company was quoting at Rs 401.75, up 4.77 percent on the BSE.
For more details click here – https://www.ways2capital.com/
intraday tips free trial on mobile
This post first appeared on After Italy Verdict Gold Trades Higher On Safe-haven Demands; Silver Down, please read the originial post: here
